Skip to main content
Lifecare ASA logo

Lifecare ASA — Investor Relations & Filings

Ticker · LIFE ISIN · NO0013355859 LEI · 254900D88MYGZ7JD5P39 OL Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2024-08-27 Interim / Quarterly Rep…
Country NO Norway
Listing OL LIFE

About Lifecare ASA

https://lifecare.no/

Lifecare ASA is a clinical-stage medical sensor company specializing in the development of nanotechnology for medical applications. Its core activity involves creating miniaturized, implantable, and long-term nanobiosensors for the continuous monitoring of various body analytes. The company's primary focus is on developing a sensor for correct and continuous glucose monitoring to improve diabetes management. The business model is based on developing and licensing its proprietary sensor technology to facilitate the production and sale of advanced medical devices.

Recent filings

Filing Released Lang Actions
LIFE: Lifecare ASA Q2 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Quarterly report Q2 2024' and contains comprehensive financial data, including a 'Key figures' table, 'Financial review', 'Financial statements', and 'Selected notes'. It provides a detailed operational and strategic update for the specific fiscal period (Q2 2024). It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report. Q2 2024
2024-08-27 English
LIFE: Lifecare ASA Q2 2024
Earnings Release Classification · 1% confidence The document explicitly states, "Today, Lifecare AS (LIFE) (the "Company") ... publishes Q2 financial report and operational update." It provides key highlights, operational milestones (longevity studies, patent filing, acquisition of RemovAid), and financial context (rights issue completion). It also announces a live presentation of these results. This structure—a brief announcement summarizing key results for a specific period (Q2 2024) without being the full, detailed financial statement—is characteristic of an Earnings Release (ER). Although it mentions publishing the 'financial report,' the text itself is a summary announcement, fitting the ER definition better than the comprehensive 'IR' (Interim Report) or the 'RPA' (Report Publication Announcement), as it contains substantive operational and financial commentary, not just a notice that a report is available. Q2 2024
2024-08-27 English
Lifecare ASA Q2 2024 presentation
Report Publication Announcement Classification · 1% confidence The document explicitly states: "LIFECARE ASA Q2 2024 PRESENTATION" and announces that the company "will release its second quarter 2024 results on Tuesday 27 august 2024". It then details the time and location for the presentation of these results and provides a link to enroll for the webcast. This is a classic announcement regarding the upcoming release of periodic financial results (Q2 2024) and the associated presentation event, rather than the full results document itself (which would be an IR or ER). Since it is announcing the release of results and the presentation, and the document is short (1501 chars), it fits the criteria for a Report Publication Announcement (RPA) which signals the release of other materials, or potentially an Earnings Release (ER) if it were the actual highlights. Given the focus on the *presentation* and the *announcement date* of the results release, RPA is the most precise fit for announcing the event surrounding the results release.
2024-08-22 English
Lifecare ASA Q2 2024 presentation
Report Publication Announcement Classification · 1% confidence The document is titled "Lifecare ASA Q2 2024 presentation" and explicitly states that the company "will release its second quarter 2024 results on Tuesday 27 august 2024". It then details a live presentation event for these results. This structure—announcing the release of periodic results and scheduling a presentation/webcast—is characteristic of an Earnings Release (ER) or a precursor/announcement related to it. However, the document itself is an announcement about the *timing* of the results release and the subsequent presentation/webcast, rather than the full results (ER) or the presentation slides (IP). Given the short length (1555 chars) and the focus on announcing the date and time of the results release and the subsequent presentation, it fits best as an announcement regarding the publication of financial information. Since it announces the release of results, it is closely tied to the Earnings Release (ER) process. If it were just announcing the presentation, it might be RPA, but since it centers on the Q2 results release date, ER is the most relevant core event. However, looking closely at the definitions, this document is an announcement *about* the upcoming earnings release and presentation. It is not the actual Earnings Release (ER) highlights, nor is it the Investor Presentation (IP). It is an announcement of the event. The closest fit among the options for an announcement about the timing of a financial report release is often RPA (Report Publication Announcement) or RNS. Since it specifically mentions the release of Q2 results and the subsequent presentation, it is an announcement related to the earnings cycle. Given the options, and the fact that it is an announcement detailing *when* the results will be released and *when* the presentation will happen, it functions as a notification about the upcoming financial event. If we must choose between ER (the results themselves) and RPA (announcement of publication), RPA is technically more accurate for this specific text, as it is a notice about the publication event. However, since the core subject is the Q2 results release, and it mentions a presentation, it is often grouped with ER materials. Let's re-evaluate based on the 'MENU VS MEAL' rule. This is not the meal (ER or IP). It is an announcement of the meal. RPA is for announcing the publication of reports. This announces the publication of results and a presentation. Therefore, RPA is the most precise fit for this announcement document type.
2024-08-22 English
LIFE Successfully completed nine weeks of longevity trials
Regulatory Filings Classification · 1% confidence The document is a press release from Lifecare ASA announcing positive results from nine weeks of longevity trials for their Sencell Continuous Glucose Monitor (CGM) sensor in a dog named Elli. It details the successful operational lifetime, biocompatibility, and comparison to existing market CGM systems. This type of announcement, focusing on clinical trial progress and operational milestones, is typically classified as an Earnings Release (ER) if it accompanies financial results, or more generally as a Regulatory Filing (RNS) if it's a standalone operational update that doesn't fit other specific categories like M&A or Capital Change. Since it is a specific announcement of operational progress and positive results, and not a full financial report (10-K, IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it's a periodic update, or RNS if it's purely operational news. Given the context of clinical stage medical sensor companies, these operational updates often serve as key news releases, similar in function to an ER announcing progress. However, since it is not explicitly tied to a quarterly/periodical financial result announcement (like 'Q3 results show...'), and is a general operational update, RNS is a safer fallback. Upon review, this reads like a significant operational milestone announcement, which often falls under general regulatory news flow. Since there is no specific category for 'Clinical Trial Update' or 'Operational Milestone', and it is not a formal financial report, RNS is the most appropriate general regulatory filing category.
2024-08-21 English
LIFE Successfully completed nine weeks of longevity trials
Environmental & Social Information Classification · 1% confidence The document is a press release dated August 21, 2024, announcing positive results from nine weeks of sensor longevity trials for a Continuous Glucose Monitor (CGM) product (Sencell). It details operational success, biocompatibility, and future study plans. This type of announcement, focusing on operational milestones and preliminary results rather than comprehensive financial statements (10-K, IR) or formal voting results (DVA), is typically classified as a general regulatory announcement or news release. Since it is not a formal Earnings Release (ER) which focuses on financial figures, nor a specific report like AR or IR, and it is not announcing the publication of a major report (RPA), the most appropriate general category for this type of corporate update is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory news.
2024-08-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.